Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer
Anderson J. Ryan(University of Oxford)
Cited by 25
Related Papers
Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer
|British Journal of Cancer|2009|65
Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
|Oncotarget|2014|46
An organotypic model for investigating drug-radiation responses in the lung
|Journal of Biological Methods|2024|1